Chemotherapy for Prostate Cancer
Jacek Pinski, MD, PhD - USC/Norris Comprehensive Cancer Center,
Los Angeles, CA
Dr. Pinski points out that there is general agreement that patients who
have metastatic hormone
refractory prostate cancer (HRPC) should receive
chemotherapy, and that the drug Taxotere® (docetaxel) has been
approved by the FDA based on improved survival data.
Dr. Pinski states that patients who fail docetaxel therapy should
be offered some other chemotherapy, but that there is currently no
FDA approved standard treatment in this case. Mitoxantrone has been used for palliative care. Studies have shown however, that
docetaxel is more effective in median survival time, and reduction
of PSA even though it causes more side effects. This makes docetaxel
the new standard of care for metastatic
Dr. Pinski presents the results of some other studies, and discusses
new studies that are underway. He also addresses several issues about
- Who should be treated with chemotherapy?
- When should chemotherapy
- When should it be stopped?
- When is intermittent chemotherapy advisable?
- What is likely to be
the best sequencing of mitoxantrone and docetaxel therapy?
- How and when should elderly PC patients be treated with
- What other drugs or supplements can be combined with
standard chemotherapy agents to make them more effective?
This presentation was one of several given at the Prostate
Cancer Research Instituteâ€™s September, 2006 conference “Improving
Treatment and Quality of Life For Men with Recurrent and Advanced
Prostate Cancer” held in Los Angeles, CA, USA. The Prostate
Cancer Research Institute (PCRI) is a 501(c)(3) charitable organization
whose mission is to improve the quality of menâ€™s lives by supporting
research and disseminating information that educates and empowers
patients, families and the medical community.
Much more information is available in our PCRI
Papers page and elsewhere
on this Web site.
More videos are listed in our Online